Comparative Pharmacology
Head-to-head clinical analysis: NORMOCARB HF 25 versus THAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORMOCARB HF 25 versus THAM.
NORMOCARB HF 25 vs THAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium channel blocker; inhibits calcium ion influx across cardiac and smooth muscle cells, resulting in dilation of coronary and systemic arteries and negative chronotropic effects.
THAM (tromethamine) is a proton acceptor that buffers hydrogen ions, treating metabolic acidosis by increasing blood pH and bicarbonate buffering capacity.
Oral: 25 mg once daily, titrate based on response; maximum 50 mg daily.
Intravenous administration of 300-500 mL of 0.3 M THAM solution (approximately 1-2 mEq/kg) over 30-60 minutes, repeated as needed based on blood pH and base deficit.
None Documented
None Documented
Terminal elimination half-life is approximately 5-7 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateMechlorethamine + Digoxin
"Mechlorethamine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMechlorethamine + Digitoxin
"Mechlorethamine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMechlorethamine + Deslanoside
"Mechlorethamine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMechlorethamine + Acetyldigitoxin
"Mechlorethamine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 1-2 hours in patients with normal renal function; prolonged up to 6-8 hours in renal impairment.
Primarily renal (80-90% as unchanged drug), with 10-20% biliary/fecal elimination.
Renal: >95% excreted unchanged in urine. Biliary/fecal: negligible (<5%).
Category C
Category C
Alkalizing Agent
Alkalizing Agent